Drugs / ADCT-502
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03125200 | May 2017 → Apr 2018 | breast cancer, gastroesophageal cancer, non-small cell lung carcinoma, urinary bladder cancer | ADC Therapeutics S.A. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADCT-502 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03125200 ↗ |
| Modality | Other / unclassified | “ADCT-502 is an antibody drug conjugate (ADC)” NCT03125200 ↗ |
| Route | Intravenous | “Intravenous Infusion” NCT03125200 ↗ |